Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 11;68(40):880-884.
doi: 10.15585/mmwr.mm6840a3.

Update: Influenza Activity - United States and Worldwide, May 19-September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine

Scott Epperson  1 , C Todd Davis  1 , Lynnette Brammer  1 , Anwar Isa Abd Elal  1 , Noreen Ajayi  1 , John Barnes  1 , Alicia P Budd  1 , Erin Burns  1 , Peter Daly  1 , Vivien G Dugan  1 , Alicia M Fry  1 , Yunho Jang  1 , Sara Jo Johnson  1 , Krista Kniss  1 , Rebecca Kondor  1 , Lisa A Grohskopf  1 , Larisa Gubareva  1 , Angiezel Merced-Morales  1 , Wendy Sessions  1 , James Stevens  1 , David E Wentworth  1 , Xiyan Xu  1 , Daniel Jernigan  1
Affiliations

Update: Influenza Activity - United States and Worldwide, May 19-September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine

Scott Epperson et al. MMWR Morb Mortal Wkly Rep. .

Abstract

During May 19-September 28, 2019,* low levels of influenza activity were reported in the United States, with cocirculation of influenza A and influenza B viruses. In the Southern Hemisphere seasonal influenza viruses circulated widely, with influenza A(H3) predominating in many regions; however, influenza A(H1N1)pdm09 and influenza B viruses were predominant in some countries. In late September, the World Health Organization (WHO) recommended components for the 2020 Southern Hemisphere influenza vaccine and included an update to the A(H3N2) and B/Victoria-lineage components. Annual influenza vaccination is the best means for preventing influenza illness and its complications, and vaccination before influenza activity increases is optimal. Health care providers should recommend vaccination for all persons aged ≥6 months who do not have contraindications to vaccination (1).

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. David E. Wentworth reports U.S. patent no. 10,272,149 for a live, synthetic, modified bat influenza virus strain useful for vaccination against a target influenza strain, outside the current work. No other potential conflicts of interest were disclosed.

Figures

FIGURE 1
FIGURE 1
Number of respiratory specimens testing positive for influenza reported by public health laboratories, by influenza virus type, subtype/lineage, and surveillance week — United States, September 30, 2018–September 28, 2019 * N = 45,619. † As of October 4, 2019.
FIGURE 2
FIGURE 2
Genetic characterization of U.S. and global viruses collected during May 19–September 28, 2019
See this image and copyright information in PMC

References

    1. Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2019–20 influenza season. MMWR Recomm Rep 2019;68(No. RR-3). 10.15585/mmwr.rr6803a1 - DOI - PMC - PubMed
    1. Barr IG, Deng YM, Grau ML, et al. Intense interseasonal influenza outbreaks, Australia, 2018/19. Euro Surveill 2019;24:1900421. 10.2807/1560-7917.ES.2019.24.33.1900421 - DOI - PMC - PubMed
    1. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(No. RR-1). - PubMed
    1. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410–7. 10.1097/00006454-200005000-00005 - DOI - PubMed
    1. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin Infect Dis 2010;51:887–94. 10.1086/656408 - DOI - PubMed

MeSH terms

Substances